NDI-101150 is a potent HPK1 (MAP4K1) inhibitor that selectively activates immune cells such as T cells, B cells, and dendritic cells. It significantly inhibits tumor growth and induces complete tumor regression in the EMT-6 mouse model.

NDI-101150 is a potent HPK1 (MAP4K1) inhibitor that selectively activates immune cells such as T cells, B cells, and dendritic cells. It significantly inhibits tumor growth and induces complete tumor regression in the EMT-6 mouse model.

BMS-986397 (CC-91633) is a potent and selective thalidomide-derived molecular glue degrader of CK1α and a modulator of CRBN E3 ubiquitin ligase. As a first-in-class CELMoD agent, it exhibits strong anti-leukemic activity in AML (Acute Myeloid Leukemia) and HR-MDS (High-Risk Myelodysplastic Syndrome) models, with enhanced efficacy and potency for hematologic malignancies and immunomodulation.

BMS-986397 (CC-91633) is a potent and selective thalidomide-derived molecular glue degrader of CK1α and a modulator of CRBN E3 ubiquitin ligase. As a first-in-class CELMoD agent, it exhibits strong anti-leukemic activity in AML (Acute Myeloid Leukemia) and HR-MDS (High-Risk Myelodysplastic Syndrome) models, with enhanced efficacy and potency for hematologic malignancies and immunomodulation.

BMS-986397 (CC-91633) is a potent and selective thalidomide-derived molecular glue degrader of CK1α and a modulator of CRBN E3 ubiquitin ligase. As a first-in-class CELMoD agent, it exhibits strong anti-leukemic activity in AML (Acute Myeloid Leukemia) and HR-MDS (High-Risk Myelodysplastic Syndrome) models, with enhanced efficacy and potency for hematologic malignancies and immunomodulation.

BMS-986397 (CC-91633) is a potent and selective thalidomide-derived molecular glue degrader of CK1α and a modulator of CRBN E3 ubiquitin ligase. As a first-in-class CELMoD agent, it exhibits strong anti-leukemic activity in AML (Acute Myeloid Leukemia) and HR-MDS (High-Risk Myelodysplastic Syndrome) models, with enhanced efficacy and potency for hematologic malignancies and immunomodulation.

MGD-28 is a potent and orally active degrader of Cereblon (CRBN)-dependent IKAROS proteins. It effectively degrades IKZF1 (DC50 = 3.8 nM), IKZF2 (DC50 = 56.3 nM), and IKZF3 (DC50 = 7.1 nM). It demonstrates significant antiproliferative potency across various hematologic cancer cell lines.

MGD-28 is a potent and orally active degrader of Cereblon (CRBN)-dependent IKAROS proteins. It effectively degrades IKZF1 (DC50 = 3.8 nM), IKZF2 (DC50 = 56.3 nM), and IKZF3 (DC50 = 7.1 nM). It demonstrates significant antiproliferative potency across various hematologic cancer cell lines.

MGD-28 is a potent and orally active degrader of Cereblon (CRBN)-dependent IKAROS proteins. It effectively degrades IKZF1 (DC50 = 3.8 nM), IKZF2 (DC50 = 56.3 nM), and IKZF3 (DC50 = 7.1 nM). It demonstrates significant antiproliferative potency across various hematologic cancer cell lines.

MGD-28 is a potent and orally active degrader of Cereblon (CRBN)-dependent IKAROS proteins. It effectively degrades IKZF1 (DC50 = 3.8 nM), IKZF2 (DC50 = 56.3 nM), and IKZF3 (DC50 = 7.1 nM). It demonstrates significant antiproliferative potency across various hematologic cancer cell lines.